ALS News Today Home | ALS News Today
2024年12月13日 · Healthcare costs increase as ALS progresses, Biogen study finds. Due to substantial increases in the use of healthcare resources, medical costs in the U.S. for people with amyotrophic lateral sclerosis (ALS) rise significantly as the disease progresses, going from about $31,000 per year in the early disease stage to $122,000 per year in the late stage, a study…
Healthcare costs increase as ALS progresses, per Biogen US study
1 天前 · Due to substantial increases in the use of healthcare resources, medical costs in the U.S. for people with amyotrophic lateral sclerosis (ALS) rise significantly as the disease progresses, going from about $31,000 per year in the early disease stage to $122,000 per year in the late stage, a study by Biogen researchers found.
News Archives - ALS News Today
Neurosense finalizing protocol for Phase 3 trial of PrimeC for ALS. Neurosense Therapeutics is working on finishing touches for the protocol of a Phase 3 study testing PrimeC, an oral treatment the company is developing for amyotrophic lateral sclerosis (ALS), and plans to submit the protocol for approval to the U.S. Food and Drug Administration (FDA) in the first…
Top 10 ALS stories of 2023 - ALS News Today
2024年1月2日 · No. 9 – Further questions set back European approval of AMX0035. Amylyx Pharmaceuticals’ application seeking the approval of AMX0035 in treating ALS patients across Europe faced a second round of questions from the Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency. The committee still had major objections to AMX0035 that needed to be addressed ...
HEALEY ALS trial to allow longer follow-up, blood cell collection
4 天之前 · The HEALEY ALS platform trial, which is simultaneously testing multiple potential treatments for amyotrophic lateral sclerosis (ALS), is amending its master protocol to allow a longer follow-up time and collection of blood cells for use in future research. Slight modifications to the enrollment ...
Medicare plans told to cover Qalsody for ALS tied to SOD1 …
6 天之前 · The directive comes after the ALS Association worked closely with the CMS, presenting evidence of widespread instances where coverage was wrongly denied patients who met all the necessary criteria for the treatment. According to the group, the order is the first of its kind to be issued by the center. Qalsody, an injectable treatment marketed by Biogen, was conditionally approved by the U.S ...
Corcept's dazucorilant fails to slow ALS disease progression in...
2024年12月17日 · The study (NCT05407324), which tested dazucorilant doses at 150 mg or 300 mg in 249 participants, also showed that gastrointestinal side effects at the start of treatment were “substantially” more common with dazucorilant than a placebo.. No deaths were reported in the high-dose group after six months, but five deaths were in the placebo group, a statistically meaningful difference.
'Living with ALS' report aims to alter for better its course in 10...
2024年6月25日 · The ALS Association is commending the National Academies of Sciences, Engineering, and Medicine for its “groundbreaking” and comprehensive report that maps a way toward making amyotrophic lateral sclerosis (ALS) a livable disease within a decade.
Largest ALS patient-based stem cell, biodata resource now open
2024年11月21日 · The largest of its kind, the repository contains biological and clinical data from nearly 1,000 ALS patients, as well as specialized nerve cells called induced pluripotent stem cells (iPSCs) derived from the patients that scientists can use as a resource for advancing ALS research and treatment.. Researchers can access the resources via the online, open-source Answer ALS Neuromine Data Portal ...
About Us - ALS News Today
ALS News Today is a digital platform intended to provide the amyotrophic lateral sclerosis (ALS) community with the most recent news and information on ALS, as well as first-hand community perspectives from our patient and caregiver columnists.. All articles on ALS News Today are original content produced by in-house writers and editors. Occasionally, we seek the opinion of outside experts for ...